Drugs Xagena
Genentech and FDA ( Food and Drug Administration ) informed HealthCare Providers of important new safety information regarding Avastain ( Bevacizumab ). Tracheoesophageal fistula has been seen in ...
The safety and maximum tolerated dose ( MTD ) of sunitinib malate( Sutent ) in combination with Bevacizumab ( Avastin ) has been assessed in patients with metastatic renal cell carcinoma ( mRCC ) in a ...
The FDA ( Food and Drug Administration ) has approved Everolimus tablets ( Afinitor ) for the treatment of patients with advanced renal cell carcinoma after failure of treatment with Sunitinib or Sora ...
The FDA ( Food and Drug Administration ) has announced that the Agency is recommending removing the breast cancer indication from the label for Avastin ( Bevacizumab ) because the drug has not been sh ...
The FDA ( Food and Drug Administration ) has approved a new use of Avastin ( Bevacizumab ) in combination with fluoropyrimidine-based Irinotecan or Oxaliplatin chemotherapy for people with metastatic ...
The European Commission ( EU ) has approved the use of Avastin ( Bevacizumab ) in combination with Paclitaxel, Topotecan, or Pegylated liposomal doxorubicin chemotherapy as a treatment for women with ...
The ASCO Task Force has applied the Framework to four clinical scenarios in which multiple trials have compared new treatment options with current standards of care: first-line treatment for metastati ...
The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer drugs fund list. The decision summaries record how each drug/drug indica ...
The FDA ( US Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) in combination with Avastin ( Bevacizumab ), Paclitaxel and Carboplatin ( chemotherapy ), for the initial ( first-li ...
The FDA ( US Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) in combination with chemotherapy ( Abraxane [ Paclitaxel protein-bound; nab-Paclitaxel ] and Carboplatin ) for the i ...
The FDA ( U.S. Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) in combination with Avastin ( Bevacizumab ) for the treatment of people with unresectable or metastatic hepatocell ...
The European Commission has approved Tecentriq ( Atezolizumab ) in combination with Avastin ( Bevacizumab ) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma ( ...
The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as a monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high ( ...
Some 90% of ovarian cancer are of epithelial cell type: among them, 75% of cases are represented by the high-grade serous ovarian cancer (HG-SOC) and the remaining 10% are non-epithelial ovarian cance ...
